Anticoagulation and cataract surgery.

Area of Science:

• Ophthalmology
• Cardiology
• Pharmacology

Background:

• Cataract surgery is a common procedure.
• Anticoagulation therapy is frequently prescribed for cardiovascular conditions.
• The safety of continuing anticoagulation during cataract surgery requires careful assessment.

Purpose of the Study:

• To evaluate the risk of hemorrhagic complications in patients undergoing cataract surgery while on anticoagulation.
• To compare outcomes between anticoagulated patients and a control group.

Main Methods:

• Retrospective audit of patients undergoing cataract surgery between January 2015 and December 2015.
• Inclusion of patients on warfarin or dabigatran.
• Comparison with a control group not on anticoagulation or antiplatelet therapy.
• Assessment of intraoperative and postoperative hemorrhage and thromboembolic events.

Main Results:

• Forty-four anticoagulated patients (warfarin or dabigatran) and 41 controls were included.
• Hemorrhagic complication rates were 18% (warfarin), 25% (dabigatran), and 11% (controls), with no statistical significance.
• Minor, non-visually significant hemorrhages were observed.
• No thromboembolic events occurred in any group.

Conclusions:

• Continuing anticoagulation with warfarin or dabigatran during cataract surgery does not lead to a statistically significant increase in hemorrhagic complications.
• The findings support the continuation of anticoagulation therapy in patients undergoing cataract surgery.
• Further research may explore optimal management strategies for anticoagulated patients.